NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12-21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback